Praxis Precision Medicines, Inc.
Praxis Precision Medicines is a clinical-stage biopharmaceutical company developing therapies for central nervous system disorders, with its primary political exposure stemming from eight pending bills with a combined estimated revenue impact of $129M.
BusinessWhat PRAX does
Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on translating genetic insights into therapies for central nervous system disorders. Its revenue is derived from research and development collaborations and is pre-commercial, with no marketed products generating significant sales. The company's pipeline targets conditions like epilepsy and movement disorders.
Lifetime Government AwardsPRAX federal contracts
PRAX doesn't hold direct federal contracts.
Verified via USASpending.gov: $0 reported in direct prime-contract awards. Companies in this position typically sell federal services indirectly through prime contractors and integrators (e.g., Lockheed Martin, Booz Allen, Microsoft Azure) or through commercial channels that don't appear in USASpending data.
Smart Money · 13F HoldingsHedge funds holding PRAX
Politicians Trading PRAXMembers of Congress with recent PRAX positions
Congressional TradesWho in Congress is trading PRAX
Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock
No Form 4 activity recorded in the last 180 days.
Bills Affecting PRAXLive legislation impacting this stock
Political ProfileWhere PRAX sits in Washington
[object Object]
STRUCTURAL: High regulatory density (95) due to eight pending pharma-sector bills with material estimated revenue impacts. EVIDENTIARY: No evidentiary signals present; zero lobbying spend (get_political_influence.lobbying.total_income: 0), zero insider buys (get_corporate_insider_signal.total_buys: 0), zero congressional trades, and zero federal contracts. Net: High structural legislative risk is unmitigated by any supportive political or financial engagement.
Regulatory ExposureThreats & opportunities
Regulatory threats
-
Broad legislative pressure on pharmaceutical pricing and drug developmentCongress"Eight recent bill_impacts with impact_ratios from 0.0021 to 0.0028 and estimated revenue impacts up to $19.5M each."
Regulatory opportunities
-
Potential for favorable drug approval pathways or research incentives within pending legislationFDA / Congress"Multiple pending pharma-sector bills (bill_impacts) indicate active legislative focus that could contain beneficial provisions."
Live signals + predictions for PRAX — for Founders
The free page above gives you the public record. Members see the real-time intelligence layer on top of it:
- Live 7-layer signal scores when Congress trades PRAX
- Bill Pass Index v2 odds for every bill on the watch list
- Iron Triangle alerts (committee × donor × trade)
- SEC Form 4 cluster detection (CEO + CFO + director buys)
- Whale-Opportunity expected-value ranking
- Custom watchlist alerts via email + Discord